Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors
- 25 January 2008
- journal article
- Published by Springer Nature in Investigational New Drugs
- Vol. 26 (2) , 159-167
Abstract
Background ZD6126 is a novel vascular-targeting agent that disrupts the endothelial tubulin cytoskeleton causing selective occlusion of tumor vasculature and extensive tumor necrosis. This Phase I clinical study was conducted to evaluate the dose and administration schedule of ZD6126. Methods Adult patients with solid tumors refractory to existing treatments received a 10-min, single-dose intravenous infusion of ZD6126 every 14 or 21 days. Subsequent dose escalation was performed, based on the incidence of adverse events (AEs) within the first cycle of drug administration. Blood samples were obtained for pharmacokinetic analysis, and the effects of ZD6126 on tumor vasculature were visualized using DCE-MRI technology. Results Forty-four patients received ZD6126 (5−112 mg/m2 in the 21-day schedule, n = 35; 40−80 mg/m2 in the 14-day schedule, n = 9). Common AEs were similar in both groups and included abdominal pain, nausea and vomiting, which appeared to be dose related. The incidence of abdominal pain at 112 mg/m2 in the 21-day study prevented further dose escalation. Pharmacokinetic studies confirmed that ZD6126 is rapidly hydrolyzed to ZD6126 phenol. There was no difference in the pharmacokinetics of ZD6126 phenol upon repeat administration or between the two dosing regimens. DCE-MRI evaluation has demonstrated the antivascular effects of ZD6126. Conclusions This study identified that ZD6126 administered every 2 or 3 weeks at 80 mg/m2 was well tolerated, with mild but manageable gastrointestinal AEs. In approximately 11% (5 out of 44) of patients, ZD6126 was associated with cardiac events categorized as dose limiting toxicities (one patient with asymptomatic decreased left ventricular ejection fraction (LVEF), two with increased troponin concentrations, one with myocardial ischemia, and one with ECG signs of myocardial ischemia).Keywords
This publication has 24 references indexed in Scilit:
- Effect of Pretreatment With Atenolol and Nifedipine on ZD6126-Induced Cardiac Toxicity in RatsJNCI: Journal of the National Cancer Institute, 2007
- Augmentation of radiation response with the vascular targeting agent ZD6126International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Phase I Clinical Evaluation of Weekly Administration of the Novel Vascular-Targeting Agent, ZD6126, in Patients With Solid TumorsJournal of Clinical Oncology, 2006
- 5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting AgentClinical Cancer Research, 2006
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126Clinical Cancer Research, 2004
- Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance ImagingJournal of Clinical Oncology, 2003
- Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissuesInternational Journal of Radiation Biology, 2001
- Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapyBritish Journal of Radiology, 1993
- Vascular attack as a therapeutic strategy for cancerCancer and Metastasis Reviews, 1990